Skip to main content

MoneyWorks4Me

Cohance Lifesciences receives USFDA EIR for Pashamylaram manufacturing facility

09 Nov 2026 Evaluate

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing facility at Pashamylaram, Hyderabad. The USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI).

Earlier, the USFDA had conducted an inspection of the aforesaid manufacturing facility from July 27, 2026, to August 5, 2026.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. 


Peers
Company Name CMP
Sun Pharma. Inds. 1907.25
Dr. Reddys Labs. 1384.65
Cipla 1419.60
Lupin 1993.45
Zydus Lifesciences 1199.50
View more..